

U.S. Food and Drug Administration Division of Pharmaceutical Quality Operations I 10 Waterview Blvd, 3<sup>rd</sup> FL Parsippany, NJ 07054 Telephone: (973) 331-4900 FAX: (973) 331-4969

www.fda.gov

October 17, 2022

Marcy Bliss, Chief Executive Officer Wedgewood Village Pharmacy, LLC 405 Heron Dr Ste 200 Swedesboro, New Jersey 08085 mbliss@wedgewoodpharmacy.com

Dear Ms. Bliss:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm's corrective actions in response to our warning letter [WL# 395218, dated February 21, 2014]. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA's implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,

Nerizza Guerin Acting Program Division Director/District Director Office of Pharmaceutical Quality Operations Division I/New Jersey District Office